- Home
- RFMZ vs VNDA Comparison
RFMZ vs VNDA Comparison
Compare RFMZ & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFMZ
- VNDA
- Stock Information
- Founded
- RFMZ 2021
- VNDA 2002
- Country
- RFMZ United States
- VNDA United States
- Employees
- RFMZ N/A
- VNDA N/A
- Industry
- RFMZ Trusts Except Educational Religious and Charitable
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- RFMZ Finance
- VNDA Health Care
- Exchange
- RFMZ Nasdaq
- VNDA Nasdaq
- Market Cap
- RFMZ 310.0M
- VNDA 275.2M
- IPO Year
- RFMZ N/A
- VNDA 2006
- Fundamental
- Price
- RFMZ $12.68
- VNDA $4.24
- Analyst Decision
- RFMZ
- VNDA Strong Buy
- Analyst Count
- RFMZ 0
- VNDA 2
- Target Price
- RFMZ N/A
- VNDA $16.50
- AVG Volume (30 Days)
- RFMZ 76.6K
- VNDA 539.9K
- Earning Date
- RFMZ 01-01-0001
- VNDA 07-31-2025
- Dividend Yield
- RFMZ 7.43%
- VNDA N/A
- EPS Growth
- RFMZ N/A
- VNDA N/A
- EPS
- RFMZ 0.65
- VNDA N/A
- Revenue
- RFMZ N/A
- VNDA $203,467,000.00
- Revenue This Year
- RFMZ N/A
- VNDA $16.86
- Revenue Next Year
- RFMZ N/A
- VNDA $39.78
- P/E Ratio
- RFMZ $21.49
- VNDA N/A
- Revenue Growth
- RFMZ N/A
- VNDA 11.78
- 52 Week Low
- RFMZ $11.28
- VNDA $3.81
- 52 Week High
- RFMZ $14.57
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- RFMZ 56.97
- VNDA 34.31
- Support Level
- RFMZ $12.55
- VNDA $4.15
- Resistance Level
- RFMZ $12.69
- VNDA $4.89
- Average True Range (ATR)
- RFMZ 0.11
- VNDA 0.16
- MACD
- RFMZ 0.02
- VNDA -0.08
- Stochastic Oscillator
- RFMZ 89.39
- VNDA 7.50
About RFMZ RiverNorth Flexible Municipal Income Fund II Inc.
RiverNorth Flex Muni Income Fund II Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.